Mesa Laboratories CEO granted 34,807 RSUs

Kadia Siddhartha reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Kadia Siddhartha reported acquisition or exercise transactions in this Form 4 filing.

Mesa Laboratories reported that President and CEO Siddhartha Kadia received a grant of 34,807 Restricted Stock Units (RSUs) linked to the company’s common stock. Each RSU represents a contingent right to receive one share of common stock.

The RSUs vest in thirds, with 1/3 of the award vesting on each anniversary date, aligning the CEO’s compensation with longer-term company performance. Following this grant, the filing shows 34,807 RSUs held directly by the CEO, and no remaining derivative positions are listed in this report.

Insights

Executive compensation analyst

Routine CEO RSU grant aligns pay with long-term share performance.

The filing shows Mesa Laboratories granting President and CEO Siddhartha Kadia 34,807 RSUs, each convertible into one share of common stock. This is structured as equity-based compensation rather than a market purchase or sale.

The RSUs vest in three equal installments on each anniversary date, encouraging multi-year retention and performance focus. Because this is a standard compensation grant with no cash transaction or unusual terms disclosed, its impact on the broader investment thesis appears routine.

Insider Trade Summary

Grant/Award: 34,807 shares

Grant/Award 1 txn

Insider Kadia Siddhartha

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units - 1	34,807	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units - 1 — 34,807 contracts (Direct)

Footnotes (3)

1. F1. Each RSU represents a contingent right to receive one share of the Issuer's common stock
2. F2. RSUs that vest 1/3 on each anniversary date
3. F3. Not Applicable

Key Figures

RSUs granted: 34,807 RSUs Underlying common shares: 34,807 shares Holdings after transaction: 34,807 RSUs +1 more

4 metrics

RSUs granted 34,807 RSUs Grant to President and CEO on April 14, 2026

Underlying common shares 34,807 shares Each RSU represents one share of common stock

Holdings after transaction 34,807 RSUs Total RSUs held directly following the grant

Vesting pattern 1/3 per year RSUs vest one-third on each anniversary date

Key Terms

Restricted Stock Units, grant/award acquisition, derivative, President and CEO

4 terms

Restricted Stock Units financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

derivative financial

"transaction_type": "derivative""

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

President and CEO financial

"officer_title": "President and CEO""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Mesa Laboratories (MLAB) disclose about CEO equity compensation in this Form 4?

Mesa Laboratories disclosed that President and CEO Siddhartha Kadia received a grant of 34,807 Restricted Stock Units. Each RSU represents a contingent right to receive one share of Mesa’s common stock, providing stock-based compensation tied directly to future company performance and share value.

How many Restricted Stock Units did MLAB’s CEO acquire in the latest filing?

The CEO acquired 34,807 Restricted Stock Units according to the Form 4. These RSUs are derivative awards that can settle into the same number of common shares, giving the executive a significant equity-based stake directly linked to Mesa Laboratories’ future stock performance.

What is the vesting schedule for the Mesa Laboratories (MLAB) CEO’s RSU grant?

The RSUs vest in three equal installments, with one-third vesting on each anniversary date of the grant. This staggered vesting schedule encourages the CEO to remain with Mesa Laboratories over several years and focus on sustained, longer-term company performance and value creation.

Does the MLAB Form 4 show any sales or purchases of common stock by the CEO?

The Form 4 reports an acquisition of 34,807 RSUs as a grant or award and does not show any open-market purchases or sales. The transaction code is “A,” indicating a compensation-related award rather than a discretionary trade in Mesa Laboratories common stock.

How many Mesa Laboratories (MLAB) RSUs does the CEO hold after this transaction?

After the reported transaction, the filing shows the CEO holding 34,807 Restricted Stock Units directly. These RSUs correspond to an equal number of underlying common shares, reflecting the CEO’s equity-based position from this specific award at the time of the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 10:49 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kadia Siddhartha

(Last) (First) (Middle)

7475 LUSK BOULEVARD

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units - 1	(1)	04/14/2026		A		34,807		(2)	(3)	Common Stock	34,807	$0	34,807	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of the Issuer's common stock

2. RSUs that vest 1/3 on each anniversary date

3. Not Applicable

	John Sakys under Power of Attorney by Siddhartha Kadia	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)